Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ubiquitin-conjugating enzyme pseudogene designated by Ensembl as ENSG00000235583 is a non-protein-coding genomic DNA sequence that resembles the active ubiquitin-conjugating enzyme gene but harbors mutations or truncations that disrupt protein production. As a pseudogene, it is classified as either processed or unprocessed, most commonly resulting from reverse-transcribed mRNA reintegrated into the genome without regulatory promoters or protein-coding capability. While formerly considered "junk DNA," some pseudogenes, when transcribed, may influence the expression of functional genes through RNA-based regulatory mechanisms, contribute to genetic diversity, or in rare cases participate in disease processes, especially cancer, via acting as non-coding RNAs. This particular entry is not a functional enzyme, receptor, or a conventional therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme pseudogene.